Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2004 3
2006 2
2007 1
2008 1
2011 1
2012 1
2014 1
2017 4
2018 3
2019 2
2020 10
2021 11
2022 20
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
[The IN-HF Registry: the history and the scientific production for the Italian cardiology community].
Rizzello V, Tinti MD, Gori M, Marini M, Palmieri V, De Gennaro L, Manca P, Matassini MV, Di Nora C, Bianco M, Carigi S, Gentile P, Leonardi G, Orso F, Gorini M, Gonzini L, Lucci D, Maggioni AP, De Maria R, Tavazzi L. Rizzello V, et al. Among authors: manca p. G Ital Cardiol (Rome). 2024 May;25(5):301-308. doi: 10.1714/4252.42293. G Ital Cardiol (Rome). 2024. PMID: 38639120 Italian.
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
Harrold E, Keane F, Walch H, Chou JF, Sinopoli J, Palladino S, Al-Rawi DH, Chadalavada K, Manca P, Chalasani S, Yang J, Cercek A, Shia J, Capanu M, Bakhoum SF, Schultz N, Chatila WK, Yaeger R. Harrold E, et al. Among authors: manca p. Clin Cancer Res. 2024 Mar 19. doi: 10.1158/1078-0432.CCR-23-4005. Online ahead of print. Clin Cancer Res. 2024. PMID: 38502113
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Germani MM, Vetere G, Giordano M, Ciracì P, Capone I, Tamborini E, Conca E, Busico A, Pietrantonio F, Piva VM, Boccaccino A, Simionato F, Bortolot M, Manca P, Lonardi S, Conca V, Borelli B, Carullo M, Del Re M, Fontanini G, Rossini D, Cremolini C. Germani MM, et al. Among authors: manca p. Front Oncol. 2024 Feb 9;13:1307545. doi: 10.3389/fonc.2023.1307545. eCollection 2023. Front Oncol. 2024. PMID: 38406172 Free PMC article.
Editors' highlight picks from 2023 in EHJ Open.
Bäck M, Banach M, Braunschweig F, De Rosa S, Flachskampf FA, Kahan T, Ketelhuth DFJ, Lancellotti P, Larsson SC, Mellbin L, Nagy E, Savarese G, Szummer K, Wahl D; European Heart Journal Open Section Editors. Bäck M, et al. Eur Heart J Open. 2024 Feb 22;4(1):oeae008. doi: 10.1093/ehjopen/oeae008. eCollection 2024 Jan. Eur Heart J Open. 2024. PMID: 38390349 Free PMC article. No abstract available.
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, Ferrari Bravo W, Ghelardi F, Ambrosini M, Manca P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, Pietrantonio F. Randon G, et al. Among authors: manca p. J Immunother Cancer. 2023 Jun;11(6):e007104. doi: 10.1136/jitc-2023-007104. J Immunother Cancer. 2023. PMID: 37277193 Free PMC article.
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani MM, Bergamo F, Ambrosini M, Cristarella E, Cerantola R, Boccaccio C, Ricagno G, Ghelardi F, Randon G, Leoncini G, Milione M, Fassan M, Cremolini C, Lonardi S, Pietrantonio F. Manca P, et al. Eur J Cancer. 2023 Jul;187:15-24. doi: 10.1016/j.ejca.2023.03.029. Epub 2023 Mar 31. Eur J Cancer. 2023. PMID: 37099945
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study.
Prete AA, Manca P, Messina M, Formica V, Frassineti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Prete AA, et al. Among authors: manca p. Eur J Cancer. 2023 Mar;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36753836 Free article. Clinical Trial.
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.
Pietrantonio F, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, Morano F, Migliore C, Niger M, Castagnoli L, Pupa SM, Marchiò C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S. Pietrantonio F, et al. Among authors: manca p. Clin Cancer Res. 2023 Feb 1;29(3):571-580. doi: 10.1158/1078-0432.CCR-22-2533. Clin Cancer Res. 2023. PMID: 36413222 Free PMC article.
64 results